“I think it’s really important that people keep signing up to these type of trials to push research forward.”
A trial looking at panobinostat for advanced cancer to see how the liver affects what happens to it in the body
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial aimed find out more about how the body absorbs and gets rid of a drug called panobinostat. It was for people with a solid tumour that had spread (advanced cancer). A
More about this trial
Panobinostat is a drug that blocks certain proteins (
One of the important jobs that the liver does is to get rid of drugs from the body. But if you have
Studying what happens to a drug in the body is called
The aims of this trial were to
- Find out more about what happens to panobinostat in people with different levels of liver function
- Learn more about the side effects of the drug
Summary of results
The study team found that it was safe to give panobinostat to people with mild to moderate liver problems.
25 people took part in this study. Of those, 15 had liver problems.
The researchers took blood samples from everyone before the first dose of panobinostat then every few hours after having the drug and a final sample after 96 hours.
The researchers looked at how long the drug stays in the body and how the liver gets rid of it. They found that people with mild to moderate liver problems had slightly higher levels of the drug in their blood samples than people who didn’t have liver problems. But having mild to moderate liver problems didn’t affect how the body absorbed the drug.
The main side effects were
- Feeling or being sick
- Tiredness (fatigue)
- Loss of appetite
- Bleeding problems
These didn’t seem to be much worse in people with liver problems.
The trial team concluded that people with mild to moderate liver problems can safely have the same starting dose of panobinostat as people who don’t have liver problems as long as doctors keep a close eye on side effects and change the dose as necessary.
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Dr Sally Clive
Experimental Cancer Medicine Centre (ECMC)